ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1855

IL-6 Promotes Systemic Bone Loss Via Upregulation Of S1PR2 In Osteoclast Precursors In a Mouse Collagen-Induced Arthritis Model

Keisuke Tanaka, Misato Hashizume, Hiroto Yoshida, Miho Suzuki and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: IL-6

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic bone loss is a hallmark of rheumatoid arthritis (RA). Inflammatory cytokines such as interleukin-6 (IL-6) promote bone resorption by osteoclasts. Recent studies have shown that sphingosine-1-phosphate (S1P) controls the migration of osteoclast precursors (OCPs) between the blood and bone marrow, in part via S1P receptor 1 (S1PR1) and S1PR2 expressed on the surface of OCPs. It has been reported S1PR1 directs positive chemotaxis along an S1P gradient, and S1PR2 inhibits S1PR1 function and mediates negative chemotaxis in the direction of S1P. The purpose of this study was to investigate whether IL-6 regulates the expression of S1PR1 and S1PR2 and whether it has any influence on the localization of OCPs during the course of bone loss.

Methods:

DBA/1J mice were immunized with bovine type II collagen (Day 0 and Day 21), and anti-mouse IL-6 receptor antibody (MR16-1) was administered intraperitoneally on the same days. On Day 14 or Day 35, femurs were excised and the trabecular bone volume of the distal femur was analyzed using micro-computed tomography. The percentage of OCPs (CD11b+Gr-1low+med) in the tibial bone marrow was measured by flow cytometry. S1PR1 and S1PR2 mRNA expression in OCPs from immunized mice was measured by real-time PCR. For in vitro study, OCPs were isolated from normal DBA/1J mice bone marrow by using a cell sorter, and were stimulated with IL-6. S1PR1 and S1PR2 mRNA expression in these OCPs was measured by real-time PCR. S1P-directed chemotaxis of OCPs was evaluated by using a transwell plate.

Results:

Trabecular bone volume was significantly lower in immunized mice than in non-immunized control mice on Day 35. Treatment of immunized mice with MR16-1 inhibited trabecular bone loss. The percentage of OCPs in tibial bone marrow was significantly higher and the mRNA expression of S1PR2 in OCPs was significantly higher in immunized mice than in control mice on Days 14 and 35. S1PR1 mRNA expression in OCPs from immunized mice did not differ from expression in non-immunized control mice . In MR16-1 treated mice, the percentage of OCPs and S1PR2 mRNA expression were each decreased compared with that in immunized mice on Day 14 but not on Day35. IL-6 induced S1PR2 mRNA expression in OCPs in a dose-dependent manner but did not induce S1PR1 mRNA expression. IL-6 stimulation significantly decreased S1P-directed chemotaxis of OCPs.

Conclusion:

These results demonstrate that IL-6 increases the percentage of OCPs in tibial bone marrow by upregulating S1PR2, and thereby plays a crucial role in systemic bone loss induced by inflammation.


Disclosure:

K. Tanaka,
None;

M. Hashizume,
None;

H. Yoshida,
None;

M. Suzuki,
None;

Y. Matsumoto,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-6-promotes-systemic-bone-loss-via-upregulation-of-s1pr2-in-osteoclast-precursors-in-a-mouse-collagen-induced-arthritis-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology